Beusterien, Kathleen http://orcid.org/0000-0001-7786-5422
Will, Oliver
Flood, Emuella
McCutcheon, Susan
Mackie, deMauri S.
Mokiou, Stella
Funding for this research was provided by:
AstraZeneca
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Article History
Accepted: 12 February 2024
First Online: 15 March 2024
Declarations
:
: This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The funding source was involved in the study design, analysis, data interpretation, writing of the manuscript, and the decision to submit the manuscript for publication.
: Kathleen Beusterien, Oliver Will, and deMauri S. Mackie are employees of Oracle, which provides consulting services to AstraZeneca. Emuella Flood and Susan McCutcheon are employees and/or stockholders of AstraZeneca. At the time of this study, Stella Mokiou was an employee and stockholder of AstraZeneca.
: Data underlying the findings described in this manuscript cannot be shared due to the content of the informed consent forms signed by the patients. Please visit our Disclosure Commitment page for guidance on the AstraZeneca Data Sharing Policy ().
: The study that provided the DCE data for the current analysis received exemption status from Pearl IRB on 4 August 2020.
: In the study that provided the DCE data for the current analysis, all respondents endorsed an electronic consent form.
: Not applicable; new analytical code was not developed for this analysis.
: All authors contributed to study conception and design and interpretation of findings. KB, OW, and MSM also contributed to data analyses and manuscript development, and EF, SMC, and SM also reviewed the manuscript and provided feedback. All authors read and approved the final manuscript.